Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Zydelig (Idelalisib),ZYD1001,2021,USA,MDV,350,68,42,58,27.5,35,70,5,10,25,30,35,40,30,20,10,15,25,30,18,8,4,12,6,15,25,30,R-CHOP,Hyper-CVAD,Rituximab,Bendamustine,0,0,0,45,35,50,20,45,35,60,2
Zydelig (Idelalisib),ZYD1002,2022,Canada,Claim Database,420,72,38,62,28.1,40,65,7,8,22,33,37,35,32,23,10,12,28,32,20,10,5,14,7,12,28,33,R-CHOP,DA-EPOCH-R,Rituximab,Obinutuzumab,0,0,0,50,40,55,25,40,35,55,3
Zydelig (Idelalisib),ZYD1003,2023,UK,MDV,280,65,45,55,26.8,30,75,3,12,28,28,32,45,28,17,10,18,22,35,15,7,3,10,5,18,22,28,R-CVP,Hyper-CVAD,Rituximab,Bendamustine,0,0,0,40,30,45,15,50,35,70,1
Zydelig (Idelalisib),ZYD1004,2023,Australia,Claim Database,380,70,40,60,29.0,38,68,6,9,24,31,36,38,31,21,10,14,26,31,19,9,4,13,6,14,26,32,R-CHOP,DA-EPOCH-R,Rituximab,Obinutuzumab,0,0,0,48,38,53,22,43,35,58,2.5
